Table 2.

Tumor response in the study population by treatment*.

Variables, n (%) or median (range)	Nivolumab group, N=32	Regorafenib group, N=58
Treatment response evaluation, n(%)	25 (78.1)	47 (81.1)
Complete response	0	2 (4.3)
Partial response	4 (16)	1 (2.1)
Stable disease	7 (28)	12 (25.5)
Progression disease	14 (56)	32 (68.1)
Objective response rate#	16%	6.4%
Disease control rate#	44%	31.9%
Durability, month	5.8 (1.8–12.2)	5.9 (1.6–27.33)
Death	17 (53.1)	28 (48.3)

*Treatment response based on those who received image evaluation including Computer tomography or Magnetic resonance image.

#The comparison of objective response rate (p=0.190) and disease control rate (p=0.309) between two groups was not statistically different.